Stephen OESTERLE

Steve is Venture Partner with Cathay Health and joined Cathay in 2021. Most recently, Steve has worked on VC and PE investments as venture partner or advisor with NEA, EQT and Temasek. Previously, Steve served as Medtronic’s Senior Vice President for Medicine and Technology and was a member of the Medtronic Executive Committee for 14 years. By forging relationships with global technology partners and technical universities, he oversaw long term internal technology investments while participating in strategic corporate investments in emerging private companies. He also served as a member of the Business Development and Strategy Committee that approved all corporate acquisitions. During his tenure at Medtronic, Steve served on more than 20 boards as a Director or observer and built a strong and enduring profile for Medtronic in the global venture capital and private equity communities. Steve currently serves on the boards of: healthcare MNC Baxter (NYSE: BAX), Boston biotech/cell therapy company Sigilon Therapeutics (NASDAQ. SGTX), Shanghai cardiovascular device company Peijia Medical (HKG: 9996), healthcare SPAC Montes Archimedes Acquisition Company (NASDAQ: MAACU), PE backed companies - GlobalLogic (Partner’s Group and CPPIB owned), a product software engineering company, SHL Medical AG (EQT minority), a market leader in auto injectors for biologics, VC backed companies Alcyone Genetic Therapies - targeted gene therapy for CNS and Paragon 28 - foot and ankle ortho medical devices. He is also on advisory boards of Alphabet’s Verily, Flex Medical and Samsung. Steve graduated summa cum laude from Harvard and received his medical degree from Yale. He completed his internship and residency at Massachusetts General Hospital. Following medical school, he completed a fellowship in Interventional Cardiology at Stanford and then served on the faculty at Stanford and Harvard Medical Schools and directed the Invasive Cardiology Services at Massachusetts General Hospital and Stanford.